ModifiedUnitedHealthcarePolicy CS150NM.E

Whole Exome and Whole Genome Sequencing (Non-Oncology Conditions) (for New Mexico Only)

Outpatient and post-discharge coverage policy for WES and WGS (non-oncology) for members in New Mexico, specifying medical necessity, ordering clinicians, and permissible/unsupported indications.

Policy Summary

PayerUnitedHealthcare

PolicyWhole Exome and Whole Genome Sequencing (Non-Oncology Conditions) (for New Mexico Only)

Policy CodePolicy CS150NM.E

Change TypeCoverage criteria revisedcounseling addedexclusions clarified

Effective DateApr 1, 2026

Next Review Date

Key ActionOrder WES/WGS only when listed medical necessity criteria are met and ensure genetic counseling is provided prior to testing.

SourceLink

POLICY UPDATE CHANGES

Genetic counseling is recommended prior to Whole Exome Sequencing or Whole Genome Sequencing to inform persons being tested about advantages and limitations.

Epigenetic signature analysis is considered unproven and not medically necessary for any indication due to insufficient evidence.

Language changed to indicate optical genome mapping (OGM) is considered unproven and not medically necessary (terminology standardized).

Policy applicability language clarified: WES/WGS (non-oncology) is applicable only to testing in an outpatient setting or upon discharge from an inpatient setting.

Coverage criteria language updated to state WES/WGS (with or without concurrent Comparator Analysis) is proven and medically necessary when listed criteria are met.

Removed requirement that WGS be performed only if CMA or WES have not been performed or were nondiagnostic.

Coverage criteria wording changed to require that test results are intended to directly impact the individual's medical management.

Clarified criteria phrasing that clinical presentation must not fit a Well-Delineated Genetic Syndrome or targeted panel should be done first if suspected.

Clarified that multiple congenital anomalies must affect at least two different organ systems.

Clarified that unexplained developmental regression criterion excludes Autism Spectrum Disorder and epilepsy.

Non-concurrent comparator analysis is proven and medically necessary when prior WES/WGS was performed and the individual meets criteria.

Reanalysis of WES/WGS data is proven and medically necessary when listed criteria are met, including timeframe and clinical change conditions.

Prenatal WES specimen language updated to specify specimen types and clarified congenital anomaly criteria for fetus (at least two organ systems or single system with relevant family history).

Medical records documentation requirements added emphasizing documentation must support medical necessity and may be requested.

Definitions added for Autism Spectrum Disorder, Congenital Anomaly, Epileptic Encephalopathy, Targeted Panel, and Well-Delineated Genetic Syndrome; removed Next Generation Sequencing and Variant of Unknown Significance definitions; updated Comparator Analysis definition.

Updated Description of Services, Clinical Evidence, and References to reflect current information and archived previous version CS150NM.D.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

NM onlyState-specific

>=18 monthsReanalysis interval

18+Distinct indications listed

31%High pooled prenatal yield

04/01/2026Policy effective

Coverage Criteria for WES/WGS (Non-Oncology)

Initial WES/WGS coverage criteria

Covered when ALL of the following are met:

Core medical necessity: The affected individual displays signs or symptoms of an undiagnosed or unexplained disorder with a suspected genetic cause; test results are intended to directly impact the individual's medical management; the clinical presentation does not fit a Well-Delineated Genetic Syndrome or disorder for which a specific test or Targeted Panel is available (if a specific genetic syndrome is suspected, a single gene or Targeted Panel should be performed prior to WES/WGS); and the test is ordered by a medical geneticist, neonatologist, neurologist, immunologist, or developmental pediatrician.

See clinical presentation criteria below.

Clinical presentation (Group A): One or more of: multiple congenital anomalies affecting at least two different organ systems; intellectual disability characterized as moderate, severe, or profound diagnosed by 18 years of age; global developmental delay; epileptic encephalopathy with onset before 3 years of age.

If any of these are present, coverage can be met in combination with core medical necessity.

Clinical presentation (Group B): Two or more of: congenital anomaly; significant hearing or visual impairment diagnosed by 18 years of age; laboratory abnormalities suggestive of an inborn error of metabolism; Autism Spectrum Disorder; neuropsychiatric condition (e.g., bipolar disorder, schizophrenia, OCD); hypotonia or hypertonia in infancy; movement or neuromuscular disorders (dystonia, ataxia, hemiplegia); unexplained developmental regression unrelated to Autism Spectrum Disorder or epilepsy; growth abnormality (failure to thrive, short stature, microcephaly, macrocephaly, or overgrowth); persistent and severe immunologic or hematologic disorder; dysmorphic features; consanguinity; first- or second-degree relative with similar clinical diagnosis.2 of list

Alternative pathway to satisfy clinical presentation criteria.

Non-concurrent Comparator Analysis

Comparator analysis (non-concurrent)

Non-concurrent comparator analysis: The affected individual meets the coverage criteria for WES or WGS AND WES or WGS has been previously performed on the affected individual.

Used to analyze comparator genomes when proband testing was previously performed.

Reanalysis coverage criteria

Reanalysis of prior WES/WGS

Reanalysis: At least 18 months have passed since the initial WES or WGS was performed; the affected individual meets the coverage criteria for WES or WGS; and either the affected individual experiences additional unexplained symptoms after the initial testing or new data/family history emerges that suggests a link between the individual's symptoms and specific genes.>= 18 months

Reanalysis is covered under these conditions.

Prenatal WES

Prenatal WES coverage

Prenatal WES: Chromosome microarray analysis (CMA) and/or karyotyping have been performed but were uninformative; WES is ordered by or in consultation with a medical geneticist or maternal‑fetal medicine (MFM) specialist; the specimen is obtained from amniotic fluid and/or chorionic villi or DNA is extracted from fetal blood or tissue; and the fetus has one or more of: multiple congenital anomalies affecting at least two different organ systems, fetal hydrops of unknown etiology, or a congenital anomaly affecting a single organ system with family history suggesting a genetic etiology.

Applicable to fetal diagnostic situations after standard cytogenetic testing is uninformative; multidisciplinary review and adequate prenatal phenotyping recommended.

Evidence summaries (diagnostic yield and clinical utility)

Evidence summaries and diagnostic yields for WES/WGS and related tests in various pediatric and diagnostic populations

GS vs ES comparative findings: Systematic reviews and cohort studies report that genome sequencing (GS/WGS) can identify additional diagnoses beyond exome sequencing (ES/WES) (pooled GS‑specific yield ~7%), but ES reanalysis may produce similar increases in some cohorts; overall pooled diagnostic yields vary by condition and study.

Albuquerque et al., Pandey et al., Chung et al., and others summarized.

High diagnostic yields in specific cohorts: Trio‑based and combined approaches (e.g., trio‑WES plus CNV‑seq) report high diagnostic yields (examples: 48.9% in severe NDD cohort; 61% for combined trio‑WES+CNV‑seq in young children with GDD), supporting utility in neurodevelopmental disorders and GDD.

Wayhelova et al., Zhang et al.

WGS utility across disorders: WGS has demonstrated variable diagnostic yields across disorders (e.g., 40% in a large clinical series) and may detect variant types not captured by ES (CNVs, noncoding, structural variants), potentially replacing multiple standard tests in selected indications.

Covered with clinical criteria

Covered when testing is supported by phenotype and prior non-diagnostic standard testing; higher yield scenarios include:

High‑yield prenatal indications: Fetal skeletal abnormalities after normal CMA/karyotype (very high incremental yields reported, e.g., ~63%); CNS anomalies with multisystem involvement (incremental yield ~32–35%); CAKUT with bilateral echogenic kidneys or multisystem CAKUT (high yields, e.g., 51% for BEKs); and congenital heart defects with extra‑cardiac anomalies (incremental yield ~35.9%).

Multiple systematic reviews/meta‑analyses report substantial incremental yields in these subgroups.

When ES/WGS is reasonable after negative standard testing: Prior nondiagnostic karyotype and chromosomal microarray (CMA/array‑CGH); adequate prenatal or clinical phenotyping justifying suspicion of a monogenic etiology; and trio testing preferred when feasible to increase diagnostic yield.

Supported across prenatal studies and cohort reports.

Postnatal/other high‑yield contexts: Neurodevelopmental disorders (GDD/ID/ASD) where ES yields ~36% and outperforms CMA; inherited retinal disease and other specific rare disease cohorts where WES/WGS improves diagnosis, especially after negative targeted tests.

Summary coverage considerations

Coverage considerations summarized from evidence and professional guidance in this document window:

Prenatal ES/WGS incremental yield: Prenatal exome/genome sequencing provides incremental diagnostic yield over CMA/karyotype (pooled incremental yield ~31% overall; higher for skeletal and multisystem anomalies); targeted case selection and multidisciplinary review increase yield.pooled incremental yield ~31%

Mellis et al., Pauta et al., and others report variable yields by phenotype.

Rapid sequencing in critically ill infants: Rapid WES/WGS and ultra‑rapid WGS demonstrate substantial diagnostic yield in critically ill inpatient infants (pooled diagnostic yield ~42%) and are supported for inpatient acute care; outpatient use is not supported.pooled diagnostic yield 42%

Evidence from meta‑analyses and randomized trials support inpatient utility; outpatient use lacks evidence.

Reanalysis:

Covered with clinical criteria

Professional‑society supported indications where WES/WGS is appropriate

Society‑endorsed indications: WES/WGS is recommended or appropriate for: individuals with congenital anomalies or developmental delay/intellectual disability (onset in childhood); individuals with unexplained epilepsy (including severe childhood‑onset epilepsies and epilepsy with comorbid ID/autism); and when targeted testing has failed to identify a causative variant.

Recommendations supported by ACMG, ILAE, NSGC, AAP and others.

Prenatal/selected obstetric scenarios: Prenatal WES/WGS may be considered for fetuses with major single or multiple anomalies when routine prenatal methods (karyotype/CMA) are non‑diagnostic and a genetics expert or multidisciplinary team considers a monogenic etiology likely; routine prenatal use without anomalies is not recommended.

ISPD and ACOG guidance emphasize indicated scenarios and multidisciplinary review.

Hearing loss and tiered testing: For infants/children with confirmed hearing loss, perform a clinical genetics evaluation and consider a tiered approach: comprehensive hearing‑loss gene panel first, followed by WES/WGS if negative or if syndromic features are present.

WES/WGS Initial Coverage Criteria

Covered when ALL of the following are met for initial WES/WGS:

Initial WES/WGS: The affected individual displays signs or symptoms of an undiagnosed or unexplained disorder with a suspected genetic cause and the test results are intended to directly impact the individual's medical management.

Clinical presentation should not fit a Well‑Delineated Genetic Syndrome or, if it does, targeted testing should be performed first.

Clinical presentation features: Includes multiple congenital anomalies affecting at least two different organ systems; unexplained developmental regression unrelated to Autism Spectrum Disorder or epilepsy; intellectual disability (moderate‑severe) diagnosed by 18 years; global developmental delay; epileptic encephalopathy with onset before age 3; or other listed features in policy clinical lists.

These features, together with core medical necessity, satisfy initial coverage criteria.

Non-concurrent Comparator Analysis

Non-concurrent Comparator Analysis (non-concurrent re-testing) is covered when BOTH are met:

Non-concurrent Comparator Analysis: 1) The affected individual meets the coverage criteria for WES or WGS; and 2) WES or WGS has been previously performed on the affected individual.

Covers analysis of additional comparator genomes after prior proband testing.

Reanalysis Coverage Criteria

Reanalysis of prior WES/WGS data is covered when ALL of the following are met:

Reanalysis: At least 18 months have passed since the initial WES or WGS was performed and the affected individual meets the criteria for WES or WGS, or the affected individual experiences additional unexplained symptoms after initial WES or WGS that cannot be explained by the results of the initial testing.>= 18 months since initial testing

Reanalysis may also be supported when new family history or data emerge suggesting a genetic link.

Prenatal WES

Prenatal WES is covered when ALL of the following are met:

Prenatal WES: Specimen is obtained from amniotic fluid and/or chorionic villi or DNA is extracted from fetal blood or tissue; chromosome microarray analysis (CMA) and/or karyotyping have been performed but were uninformative; WES is ordered by or in consultation with a medical geneticist or maternal‑fetal medicine specialist; and the fetus has multiple congenital anomalies affecting at least two different organ systems, or fetal hydrops of unknown etiology, or a congenital anomaly affecting a single organ system with family history suggesting a genetic etiology.

Documentation of prior nondiagnostic CMA/karyotype and detailed prenatal phenotyping is required to justify testing.

This policy addresses genome-wide sequencing modalities and related technologies. Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) are the primary covered technologies when the policy criteria are met. Related methods — including whole transcriptome sequencing (RNA-seq), epigenetic signature (episignature) analysis, and optical genome mapping (OGM) — are described for context but are not accepted as routine replacements for WES/WGS in standard diagnostic pathways due to limited or investigational status.

The document explains the intended role of transcriptome sequencing (it interrogates RNA and can provide complementary information to DNA-based tests) and describes OGM as a mapping approach to detect structural variants; episignature analysis evaluates DNA methylation patterns. Although these technologies may be useful in selected research or adjunctive scenarios, the policy considers them investigational or unsupported for routine diagnostic use in most clinical indications.

External evidence reviews (Hayes) and systematic reviews identified populations where the quality or quantity of evidence is limited. For example, Hayes concluded there is insufficient evidence to support WES or WGS for adults with suspected neuromuscular or movement disorders and found limited, low-quality evidence for using broad genetic testing to guide management in some adults with Autism Spectrum Disorder.

These evaluations underscore that coverage decisions rely on demonstrated clinical utility in the specific population under consideration; indications lacking higher-quality prospective or outcome-focused evidence may remain unsupported until additional data are available.

Multiple systematic reviews and society guidance note that performing prenatal exome/genome sequencing in fetuses with an apparently normal phenotype after a normal karyotype and CMA yields very low incremental diagnostic return; a pooled incremental diagnostic yield of 1.6% was reported in the review of fetuses tested without ultrasound-detectable anomalies.

Professional guidance (ACOG, ISPD) therefore does not support routine prenatal sequencing for phenotypically normal pregnancies and recommends reserving prenatal WES/WGS for pregnancies with fetal structural anomalies or when multidisciplinary review suggests a monogenic etiology.

Several technologies and uses are considered to have insufficient evidence for routine coverage. The policy identifies whole transcriptome sequencing as lacking sufficient clinical utility data for broad diagnostic use, noting limitations including small studies and tissue-specific expression constraints.

Similarly, epigenetic signature (episignature) analysis and optical genome mapping (OGM) are described as promising but investigational; available studies are preliminary and do not yet establish consistent clinical benefit across common diagnostic scenarios.

In addition, rapid and ultra-rapid sequencing modalities (rWES, rWGS, urWGS) have demonstrated utility in critically ill inpatient infants but current evidence is insufficient to support their routine use in outpatient settings.

The policy reiterates that routine prenatal exome or genome sequencing is not supported as a screening or first-line test in pregnancies without fetal anomalies. Prenatal WES/WGS should generally follow nondiagnostic standard cytogenetic testing (karyotype and CMA) and be limited to pregnancies with documented structural anomalies or other features that raise a reasonable suspicion of a monogenic disorder.

Ordering prenatal genome-wide testing without prior negative standard testing or without an appropriate fetal phenotype is not aligned with current evidence and guidance and therefore is not supported by the policy.

Based on current evidence reviews and the policy update, epigenetic signature analysis is considered investigational and not medically necessary for any indication because there is insufficient evidence demonstrating clinical utility and benefit.

Although episignature testing can yield diagnoses in selected cohorts, the policy classifies the approach as unproven for routine clinical application pending further validation and consistent outcome data.

Optical genome mapping (OGM) is currently considered investigational and not medically necessary for routine clinical use. Proof-of-principle studies demonstrate concordance with standard cytogenetic assays in limited series, but larger clinical utility studies and standardization are needed before OGM is adopted as a replacement for established diagnostic tests.

Consequently, OGM is not supported as a routine alternative to CMA, karyotype, WES, or WGS in standard diagnostic pathways at this time.

The policy lists several unsupported or not medically necessary uses: outpatient rapid/ultra-rapid sequencing (rWES/rWGS/urWGS) outside critically ill inpatient contexts, routine use of whole transcriptome sequencing, epigenetic signature analysis, and optical genome mapping (OGM) for general diagnostic screening or first-line evaluation.

Additionally, prenatal cell-free fetal DNA testing to perform WES/WGS, and preimplantation genetic testing (PGT) in embryos using WES/WGS approaches, are identified among uses that are not supported due to insufficient evidence or inappropriate clinical application.

Hayes reviews and systematic assessments found insufficient or limited evidence to support the routine use of WES/WGS for some adult and pediatric neurologic populations, including adults with suspected neuromuscular or movement disorders and certain presentations of autism spectrum disorder.

These conclusions reflect low-quality or sparse outcome data in these groups and indicate that broad adoption of WES/WGS for these specific neurologic indications requires further prospective research demonstrating clinical impact.

Pooled analyses and systematic reviews report that WGS provides only a modest incremental diagnostic yield over WES in many cohorts; for example, WGS did not significantly outperform WES across pooled prenatal and postnatal studies in some systematic reviews. As a result, the policy does not support routine replacement of WES by WGS without specific justification.

WGS may offer advantages in particular situations (e.g., detection of noncoding, structural, or mitochondrial variants, or when DNA quantity/turnaround time considerations apply), but current evidence does not justify universal substitution of WES with WGS.

Summary of unsupported uses includes: outpatient rWES/rWGS/urWGS (outside critically ill inpatient indications), routine whole transcriptome sequencing as a first-line test, optical genome mapping (OGM), and epigenetic signature analysis for general diagnostic purposes. These modalities are categorized as investigational or not medically necessary pending stronger evidence of clinical benefit.

Providers should therefore reserve these approaches for clearly justified, documented, and often investigational or specialty contexts rather than routine diagnostic workflows.

Reiterating the policy position: epigenetic signature analysis is designated not medically necessary for all indications in this policy update due to insufficient evidence of efficacy and clinical utility.

Although some cohorts report diagnostic yields, consistent validation, standardized interpretation frameworks, and outcome data are lacking to support routine clinical coverage.

Restating the OGM stance: optical genome mapping (OGM) is considered investigational and not medically necessary. Early studies demonstrate technical potential but do not yet provide the clinical validation or outcome data required for coverage in routine care.

OGM should be considered experimental until larger, high-quality studies establish its diagnostic yield, reproducibility, and impact on management compared with existing standard tests.

Indications Supported for Coverage

Undiagnosed or unexplained disorder with suspected genetic cause where results will directly impact management and presentation meets specified clinical features (see criteria sets)

Covered when the affected individual's presentation meets specified clinical features and results are intended to directly impact management:

Undiagnosed or unexplained disorder with suspected genetic cause: The affected individual has an undiagnosed or unexplained disorder suspected to be genetic and the result of testing is expected to directly impact medical management; clinical presentation includes one or more Group A features or two or more Group B features as described in the clinical presentation criteria.

See Initial WES/WGS coverage criteria for full feature lists.

Prenatal WES for fetal anomalies when CMA/karyotype uninformative and ordered by/with genetics or MFM specialist

Prenatal WES (fetal anomalies): CMA and/or karyotyping performed and uninformative; adequate prenatal phenotyping supports suspicion of monogenic etiology; WES ordered by or in consultation with a medical geneticist or maternal‑fetal medicine specialist; specimen from amniotic fluid/CVS or fetal blood/tissue; fetus has multiple congenital anomalies affecting at least two organ systems, fetal hydrops of unknown etiology, or single‑system congenital anomaly with family history suggestive of genetic etiology.

Provider Responsibilities, Ordering, and Documentation

Documentation Required

Provider responsibilities and medical record requirements

WES/WGS must be ordered by an appropriate specialist (medical geneticist, neonatologist, neurologist, immunologist, developmental pediatrician, maternal-fetal medicine specialist/perinatologist for prenatal orders) and the medical record must contain documentation that fully supports medical necessity. Documentation should include relevant medical history, physical exam findings, three‑generation family history when available, results of prior diagnostic testing (e.g., CMA, karyotype, targeted panels, single‑gene testing), detailed phenotyping (prenatal imaging findings for fetal cases), and a clear explanation of how test results are intended to directly impact medical management.

Ordering providers: medical geneticist, neonatologist, neurologist, immunologist, developmental pediatrician, maternal‑fetal medicine specialist (prenatal)
Medical record requirements: relevant medical history, physical exam, three‑generation pedigree, prior test results, detailed phenotype, imaging reports (prenatal)
Documentation must be legible and available upon request
Genetic counseling is strongly recommended prior to testing

Procedure and Billing Codes

Applicable Procedure/Category I and Proprietary Codesmixed

0094U	Genome (e.g., unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis.
0212U	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband.
0213U	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator genome (e.g., parent, sibling).
0214U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband.
0215U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (e.g., parent, sibling).
0260U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping.
0264U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping.
0265U	Rare constitutional and other heritable disorders, whole genome and mitochondrial DNA sequence analysis, blood, frozen and formalin-fixed paraffin-embedded (FFPE) tissue, saliva, buccal swabs or cell lines, identification of single nucleotide and copy number variants.
0266U	Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene expression by whole-transcriptome and next-generation sequencing, blood, formalin-fixed paraffin- embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression change.
0267U	Rare constitutional and other heritable disorders, identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping and whole genome sequencing.

1–10 of 28

1/3

Genome sequencing CPT codesCPT

81426	Genome (e.g., unexplained constitutional or heritable disorder or syndrome); sequence analysis
81427	Genome (e.g., unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence

Regulatory/Informationalmixed

N/A	FDA and CLIA references; no specific CPT/HCPCS codes listed in this section

Regulatory Links (informational)mixed

https://www.fda.gov/medicaldevices/deviceregulationandguidance/ivdregulatoryassistance/ucm124105.htm	FDA informational page on IVD regulatory assistance (accessed June 27, 2025).
https://www.fda.gov/medical-devices/in-vitro-diagnostics/nucleic-acid-based-tests	FDA list of cleared/approved nucleic acid-based tests (accessed June 27, 2025).

Reanalysis interval — minimum interval for reanalysis

Minimum reanalysis interval>= 18 months since initial WES/WGS

Conditions required at reanalysisAffected individual meets WES/WGS coverage criteria and either new unexplained symptoms emerged or new data/family history suggests gene link

PurposePeriodic re-evaluation using updated gene panels, improved annotation, CNV detection, and phenotype correlation to identify previously unrecognized diagnostic variants

Definitions and Terminology

Comparator Analysis definition

DefinitionGenetic evaluation of an individual's close relative(s) to aid interpretation of the individual's test results, typically a child and their biological parents (trio testing)

Common usePerformed to help classify variants (e.g., de novo vs inherited) and improve diagnostic accuracy

Policy noteComparator Analysis definition was updated in the policy; details reflected in the Definitions section

Well-Delineated Genetic Syndrome — definition and implications for testing sequence

DefinitionA syndrome with recognizable traits or abnormalities that tend to occur together and are associated with a specific disease; distinguishing characteristics (facial features, lab tests, or family history) can identify the syndrome

Implication for testing

Eligibility and Preconditions for Coverage

Family history consistent with a similar clinical diagnosis in a first- or second-degree relative supports meeting the policy's clinical-presentation requirements and may strengthen justification for WES/WGS when the testing aims to clarify a suspected inherited etiology.

Documentation of family history and pedigree information is recommended in the medical record to demonstrate how the family history contributes to the clinical suspicion and to facilitate interpretation (for example, guiding trio or extended family testing).

This policy includes several policy-specific eligibility details and expectations for documentation. Ordering clinicians should document the clinical phenotype, prior testing, and rationale for genome-wide testing in the medical record; family history that supports a suspected inherited condition can help meet eligibility requirements.

Although exact family-history thresholds are not rigidly prescriptive, the presence of similarly affected relatives (first- or second-degree) is explicitly noted as supportive evidence in coverage determinations.

A family history of a similar clinical diagnosis in a first- or second-degree relative is specifically called out as supportive documentation that may help satisfy the policy's clinical presentation criteria for genome-wide testing.

Providers should include pedigree and family-history details in the record to substantiate how the family history informs the testing rationale and choice of comparator analysis when applicable.

The policy repeatedly emphasizes the importance of family history as corroborating evidence. When available, parental or affected-relative testing (trio/quad approaches) often improves interpretability and diagnostic yield and should be documented when pursued.

Services and Uses Not Covered

The policy explicitly lists services and contexts that are not covered, including prenatal cell-free fetal DNA testing for WES/WGS purposes, preimplantation genetic testing (PGT) in embryos using WES/WGS, and outpatient use of rapid or ultra-rapid sequencing (rWES/rWGS/urWGS).

Whole transcriptome sequencing, epigenetic signature analysis, and optical genome mapping (OGM) are also identified among methods that are considered investigational or not medically necessary for routine clinical use.

Optical genome mapping (OGM) and epigenetic signature analysis are described in the policy as technologies under investigation; owing to limited clinical-validation and outcome data they are classified as investigational and their routine use is not covered.

The policy therefore treats OGM and episignature testing as not covered outside of research or specialized, well-documented circumstances where experimental testing is explicitly appropriate.

Routine prenatal exome or genome sequencing for fetuses with an apparently normal phenotype after normal standard testing (karyotype/CMA) is not supported by the evidence — pooled incremental yield is very low — and the policy lists this scenario as not covered.

Prenatal sequencing should be reserved for fetuses with structural anomalies or other features that justify a high pre-test probability of a monogenic condition.

The policy explicitly states that routine outpatient use of rapid sequencing modalities (rWES/rWGS/urWGS) is not covered; those rapid approaches have demonstrated utility in critically ill inpatient infants but lack evidence supporting outpatient application.

Similarly, whole transcriptome sequencing, OGM, and epigenetic signature analysis are not covered for routine clinical use given the current evidence base.

Background and Description of Services

Background: WES interrogates the protein-coding exons — the exome — which comprises approximately 1–2% of the genome and contains the majority of known disease-causing variants. WGS sequences the entire genome and can detect coding and noncoding variants, copy-number variants, structural variants, repeat expansions, and mitochondrial variants that may be missed by WES.

Interpretation of genome-wide sequencing yields many variants of uncertain significance and relies on laboratory analytic methods, annotation, and clinical correlation; the clinical utility of results depends on test selection, phenotyping, and expert interpretation.

Policy Revision History and Key Changes

2026-04-01policy_revisionLatest

Multiple substantive updates: added recommendation for genetic counseling prior to WES/WGS; declared epigenetic signature analysis unproven and not medically necessary; standardized terminology for optical genome mapping (OGM); clarified outpatient applicability of the policy; revised coverage criteria to state WES/WGS (with or without concurrent Comparator Analysis) is proven and medically necessary when listed criteria are met; removed prior requirement restricting WGS after CMA/WES; and clarified clinical presentation and prenatal specimen/organ-system criteria.

clarification

Revised wording across criteria to clarify that clinical presentation must not fit a Well-Delineated Genetic Syndrome or that targeted testing be performed first if a specific syndrome is suspected; clarified that multiple congenital anomalies must affect at least two organ systems and that unexplained developmental regression excludes ASD and epilepsy.

Policy Summary

PayerUnitedHealthcare

PolicyWhole Exome and Whole Genome Sequencing (Non-Oncology Conditions) (for New Mexico Only)

Policy CodePolicy CS150NM.E

Change TypeCoverage criteria revisedcounseling addedexclusions clarified

Effective DateApr 1, 2026

Next Review Date

Key ActionOrder WES/WGS only when listed medical necessity criteria are met and ensure genetic counseling is provided prior to testing.

SourceLink

On This Page

Stranneheim et al., Lowther et al.

Limitations and heterogeneity: Substantial heterogeneity across studies, variable reporting of trio versus proband‑only testing, limited long‑read GS representation, and variable clinical utility reporting limit generalizability of pooled estimates.

Meta‑analyses and clinical utility evaluations (e.g., Chung, Hayes) note these limitations.

Meta‑analyses and cohort studies support ES/WGS as first‑ or second‑tier depending on context.

Periodic systematic reanalysis of ES/WGS data increases diagnostic yield due to newly described gene‑disease associations, improved bioinformatics, CNV detection, and variant reinterpretation; reanalysis intervals are commonly on the order of ~18 months or longer depending on context.

examples: increased yields reported in reanalysis studies

ACMG guidance and cohort data support reanalysis policies and intervals.

Whole transcriptome sequencing (RNAseq) and adjunct tests: Routine use of whole transcriptome sequencing is not supported by sufficient evidence for most constitutional disorders; RNAseq may add yield in select cases (e.g., splicing defects) but is limited by tissue availability and specificity.

Consider as second‑tier adjunct in unresolved cases.

Optical Genome Mapping and Episignature testing: OGM and epigenetic episignature analyses currently lack sufficient evidence for routine clinical use and are considered investigational or not medically necessary for most indications.

Early studies show promise but further validation is required.

ACMG practice resource recommends this tiered strategy and provider awareness of panel content.

Reanalysis and periodic reevaluation: Professional guidance recommends periodic reanalysis/reevaluation of sequencing data because phenotypes and variant evidence evolve over time; laboratories should have policies for variant and case‑level reanalysis.

ACMG and ILAE statements support reanalysis.

Trio testing preferred when feasible to improve interpretation and yield.

Unexplained neurodevelopmental disorders, GDD, ID, cerebral palsy, and other pediatric genetic conditions — substantial diagnostic yield evidence

High‑yield NDD indications: Multiple studies show substantial diagnostic yields for trio‑based ES/WES and combined approaches (e.g., trio‑WES plus CNV‑seq), with reported yields up to ~48.9% in severe NDD cohorts and higher in selected GDD cohorts (e.g., combined yield 61%).

Wayhelova et al., Zhang et al., Gonzalez‑Mantilla, Srivastava are representative sources.

Prenatal structural anomalies with prior nondiagnostic karyotype/CMA — high incremental diagnostic yields

Prenatal skeletal and multisystem anomalies: ES shows very high additional detection rates in fetal skeletal abnormalities (e.g., pooled additional detection ~63%) and substantial incremental yields in multisystem CNS anomalies and other multisystem prenatal phenotypes.

Jiang et al., Mellis et al., Blayney et al.

Neurodevelopmental disorders and suspected monogenic rare diseases — ES often higher yield than CMA; recommended first-line in many contexts

NDD first‑line recommendations: Meta‑analyses and practice resources report ES diagnostic yields around 36% in NDDs and conclude ES outperforms CMA, supporting ES as a first‑ or early‑line test in many NDD evaluations.

Srivastava et al., Carss et al.

Prenatal evaluation of fetal structural anomalies after nondiagnostic CMA/karyotype, especially multisystem anomalies or relevant family history

Prenatal sequencing indications: Evidence supports prenatal ES in fetuses with structural anomalies after nondiagnostic CMA/karyotype, with pooled incremental yield around 31% and higher yields in multisystem cases; trio testing may increase yield though solo approaches can also be informative.pooled incremental yield ~31%

ISPD, ACMG, and systematic reviews support targeted use after multidisciplinary review.

Diagnostic evaluation of critically ill hospitalized infants using rWES/rWGS/urWGS — supported in inpatient critical care; not supported outpatient

Rapid/ultra‑rapid sequencing in critically ill infants: Rapid WES/WGS (rWES/rWGS) and ultra‑rapid WGS (urWGS) demonstrate substantial diagnostic yield in critically ill inpatient infants and are supported for inpatient use; current evidence does not support outpatient use.pooled diagnostic yield ~42%

Kingsmore et al., Xiao et al. provide supporting evidence.

Postnatal evaluation of congenital anomalies, developmental delay/intellectual disability, or hearing loss where genetic etiology suspected after initial evaluation

Postnatal indications: ACMG and AAP guidance support the use of WES/WGS as first‑ or second‑tier tests depending on context for congenital anomalies, developmental delay/intellectual disability, and hearing loss; reanalysis is recommended when initial testing is nondiagnostic.

Clinical genetics evaluation and consideration of CMA as first‑tier in some contexts advised.

Congenital anomalies, developmental delay, intellectual disability (onset in childhood) — WES/WGS supported as first- or second-tier testing

ACMG guidance supported uses: ACMG practice resource and guideline support WES/WGS as first‑ or second‑tier testing for individuals with congenital anomalies or developmental delay/intellectual disability with onset in childhood.

Use depends on clinical scenario and prior testing; reanalysis recommended when appropriate.

Unexplained epilepsy, especially early-onset and epilepsy with ID/autism — WES/WGS recommended

Epilepsy indications: Professional guidance (ILAE, NSGC) recommends WES/WGS for severe childhood‑onset epilepsies, epilepsy with intellectual disability or autism, and progressive myoclonus epilepsies; genetic counseling before and after testing is recommended.

Periodic reanalysis recommended for suspected genetic epilepsy without diagnosis.

Infants/children with confirmed hearing loss — genetic testing including panels, WES/WGS as tiered approach

Hearing loss testing pathway: Clinical genetics evaluation including counseling is standard; if syndromic features suggest a specific etiology perform targeted testing, otherwise begin with a comprehensive hearing‑loss gene panel and proceed to WES/WGS if negative or if broader testing indicated.

Providers should be aware of panel content and testing platform performance.

Prenatal cases with fetal structural anomalies or recurrent undiagnosed affected pregnancy when prior standard testing is non-diagnostic — consider prenatal WES/WGS

Prenatal recurrent or complex cases: Consider prenatal WES/WGS for current pregnancies with major single or multiple anomalies after nondiagnostic standard testing, or for recurrent undiagnosed affected pregnancies; testing decisions should involve genetics specialists and may include testing of prior affected tissue or parental sequencing when fetal samples are unavailable.

ISPD and ACOG provide scenarios and recommend multidisciplinary review.

Summary of covered indications including undiagnosed disorders with suspected genetic cause where results are intended to directly impact medical management; prenatal anomalies; reanalysis and comparator analysis when criteria met

Summary of covered indications including undiagnosed disorders with direct impact on management; prenatal anomalies; reanalysis and comparator analysis when criteria met

Covered indications summary: WES/WGS (with or without concurrent Comparator Analysis) is covered when the individual has an undiagnosed or unexplained disorder suspected to be genetic and test results are intended to directly impact management; prenatal WES is covered after nondiagnostic CMA/karyotype for specified fetal anomalies; non‑concurrent comparator analysis and reanalysis are covered when policy‑specified criteria (including time intervals) are met.

Refer to detailed criteria sets above for operationalizing coverage determinations.

Prior Authorization

Prenatal sequencing following negative CMA/karyotype

Prenatal sequencing (WES or WGS) should be considered when fetal imaging or clinical evaluation reveals anomalies and standard cytogenetic testing is nondiagnostic. Specifically, prenatal WES is medically necessary when chromosome microarray analysis (CMA) and/or karyotyping has been performed but uninformative, the test is ordered by or in consultation with a medical geneticist or maternal‑fetal medicine specialist, the specimen is obtained from amniotic fluid/CVS or fetal tissue/blood, and the fetus has multiple congenital anomalies affecting ≥2 organ systems, fetal hydrops of unknown etiology, or a single‑system congenital anomaly with a family history suggestive of a genetic etiology. Prenatal testing should be prioritized when detailed phenotyping suggests a monogenic disorder and after multidisciplinary review when appropriate.

Prenatal prerequisite testing: nondiagnostic karyotype and/or CMA required before prenatal WES/WGS unless a multidisciplinary genetics team documents justification for concurrent testing
Specimen types acceptable: amniotic fluid, chorionic villi sampling (CVS), fetal blood or tissue
Ordering clinicians: medical geneticist or maternal‑fetal medicine specialist

Billing Rule

Coding references relevant to authorization

CPT codes for genome sequencing are referenced for authorization and billing. Use 81426 for the primary genome sequence (Genome sequence analysis) and 81427 for re‑evaluation of a previously obtained genome sequence (e.g., updated knowledge or additional unrelated condition). List comparator genome analyses (parents, siblings) separately as applicable.

Primary genome sequencing: CPT 81426
Comparator genome (each additional): CPT 81426 (listed separately as applicable)
Re‑evaluation (reanalysis): CPT 81427

Note

Test selection rationale and sequencing modality preference

Select the sequencing modality based on phenotype, prior testing, and testing goals. When the clinical presentation is nonspecific or overlaps many possible etiologies, genome‑wide approaches (WES or WGS) or CMA may be preferred. When a well‑delineated syndrome is suspected, perform targeted single‑gene testing or a curated targeted panel first. If WES/WGS is chosen, consider trio testing (proband plus parents) when feasible because diagnostic yield is higher for trio analyses.

Targeted testing first: single‑gene or targeted panel when specific disorder suspected
Preference: consider ES (WES) as first‑line in many postnatal indications; WGS may be considered when structural variants or noncoding regions are likely relevant or when prior WES/CMA are nondiagnostic
Trio sequencing increases diagnostic yield and is preferred when feasible

Note

Evidence on ES reanalysis versus GS and reanalysis considerations

When initial WES is nondiagnostic, consider either periodic ES reanalysis or progression to WGS. Recent evidence shows WGS can identify additional diagnoses after negative ES (pooled GS‑specific yield ~7%), but ES reanalysis may produce similar or higher additional diagnostic yield in some studies; thus reanalysis of ES data (periodically, e.g., every 1–2 years or when new clinical information emerges) is a reasonable alternative to immediate WGS. Choice between ES reanalysis and WGS should be guided by prior testing quality, phenotype evolution, and the likelihood that noncoding, structural, or poorly captured regions account for the suspected diagnosis.

ES reanalysis diagnostic yield may be similar to or exceed incremental yield of WGS in some cohorts
GS (WGS) identifies diagnoses not detectable by ES in a subset (~7% pooled GS‑specific yield)
Consider factors: time since prior testing, new symptoms, quality/coverage of initial ES, and suspected variant type (CNV, SV, noncoding)

Prior Authorization

Recommended testing sequence and tiered approaches

Recommended testing sequences depend on clinical context. Examples: for global developmental delay/intellectual disability, perform CMA as a first‑tier agnostic test with WES performed either sequentially or concurrently; for hearing loss, perform a comprehensive hearing loss gene panel first, followed by genome‑wide testing (WES/WGS) if the panel is nondiagnostic. If initial WES/WGS is nondiagnostic, consider reanalysis or progression to the alternative genome‑wide modality (WGS if WES was performed) or targeted testing of additional family members when indicated.

GDD/ID: CMA first‑tier, WES sequential or concurrent; if WGS is performed first, CMA may be deferred
Hearing loss: targeted comprehensive panel → WES/WGS if negative
If initial genome‑wide test nondiagnostic: consider ES reanalysis every 1–2 years or WGS, and testing of additional family members for segregation analysis

Denial Risk

Documentation risk and denial triggers

Insufficient or incomplete clinical information and documentation may lead to denial or delay of authorization. Laboratories and reviewers may request full medical records, imaging, pedigrees, and prior test reports to confirm that criteria are met. Providers are responsible for submitting complete clinical rationale, prior testing results, and detailed phenotype to support medical necessity.

Denial triggers: requests for WES/WGS without meeting clinical criteria, prenatal testing without fetal anomalies or without prior nondiagnostic CMA/karyotype, requests for unproven indications (fetal demise evaluation, cfDNA‑based prenatal testing, PGT in embryos, outpatient rWES)
Documentation risk: inadequate phenotype, missing prior test results, or lack of specialist order/consultation may result in noncoverage

If a Well‑Delineated Genetic Syndrome is suspected, a single‑gene or targeted panel test should be performed prior to WES/WGS

Policy statusUpdated definition present in policy; targeted testing preferred when syndrome is suspected

Whole Exome Sequencing (WES) definition

DefinitionWhole Exome Sequencing (WES): DNA analysis technique that sequences the exome — the protein‑coding regions (exons) of the genome — representing ~1-2% of the genome

ScopeTargets all exons simultaneously to identify variants more efficiently than single‑gene sequencing

LimitationsGenerates large lists of variants and depends on laboratory analytic and interpretation practices for diagnostic yield

Whole Genome Sequencing (WGS) definition

DefinitionWhole Genome Sequencing (WGS): determines the sequence of all nucleotides in an individual's DNA, covering coding and noncoding regions

ScopeCan detect SNVs, indels, CNVs, structural variants, repeat expansions, and non‑exonic regulatory or splicing variants

InterpretationResults include many variants and interpretation relies on similar databases and processes used for WES, focusing primarily on exons for clinical interpretation

Whole Exome Sequencing (WES) — alternate phrasing/definition

Alternate phrasingWES: sequence determination of the exome — the protein‑coding portion of the genome (exons), comprising approximately 1-2% of the genome

Clinical emphasisMost known disease‑causing variants occur in exons; WES provides efficient simultaneous analysis of these regions

Analytic dependencyDiagnostic success depends on laboratory ability to consistently identify disease‑causing mutations

Whole Genome Sequencing (WGS) — alternate phrasing/definition

Alternate phrasingWGS: determines the order of all nucleotides in an individual's DNA and can detect variations across the genome including CNVs and structural variants

Clinical roleWGS may identify variants not captured by WES (noncoding, structural, mitochondrial) and can in some cohorts improve diagnostic yield

Evidence noteGS improved diagnostic yield in specific rare disease cohorts but impact on outcomes varies across studies

Whole Transcriptome Sequencing — definition

DefinitionWhole Transcriptome Sequencing: analyzes all RNA transcripts in a tissue (coding and noncoding RNA) to provide information complementary to DNA sequencing

Potential useCan inform on splicing and expression effects and may add diagnostic yield in select cases when appropriate tissue is available

LimitationsClinical use is limited by tissue‑specific expression and currently insufficient evidence for routine diagnostic use

Optical Genome Mapping (OGM) — definition

DefinitionOptical Genome Mapping (OGM): imaging of very long single DNA molecules labeled at specific sites to construct a genome 'map' for detection of structural variants

CapabilityCan identify insertions, deletions, duplications, inversions, and translocations and determine location/orientation of structural changes

Policy statusOGM is under study and considered investigational/unsupported for routine clinical use in this policy

Epigenetic signature analysis — definition

DefinitionEpigenetic signature analysis: evaluates chemical modifications affecting gene expression (which genes are turned on/off)

Potential useStudied for clinical applications such as diagnosing disorders with characteristic episignatures

Policy statusCurrently under study and considered unproven and not medically necessary for routine clinical use

Incremental diagnostic yield — definition

DefinitionIncremental diagnostic yield: the additional proportion of cases with pathogenic/likely pathogenic findings identified by ES/WGS beyond what was detected by prior standard testing (karyotype and CMA)

UsageUsed to quantify added diagnostic value of ES/WGS after nondiagnostic standard cytogenetic testing in prenatal and postnatal settings

ExamplePooled incremental prenatal ES yield over CMA/karyotype reported ~31% in meta‑analysis (Mellis et al.)

Trio/Quad sequencing — definition and role in interpretation

DefinitionTrio/Quad sequencing: sequencing the proband plus both parents (trio) or two fetuses plus parents (quad) to improve variant interpretation and diagnostic yield

Role in interpretationHelps determine de novo vs inherited status of variants and can increase diagnostic yield compared to proband‑only testing in many cohorts

Policy noteTrio testing is preferred when feasible and commonly used in prenatal and pediatric evaluations to enhance yield

Rapid/ultra-rapid sequencing — definition and intended inpatient use

DefinitionRapid/ultra‑rapid sequencing (rWES, rWGS, urWGS): genomic sequencing with accelerated turnaround times developed for critically ill inpatient infants to provide timely diagnostic information

Intended useDesigned for use in critically ill hospitalized infants where rapid results can impact acute management

Policy limitationEvidence supports inpatient use; outpatient use of these rapid modalities is not supported by current evidence

Reanalysis — periodic re-evaluation of ES/GS data

DefinitionReanalysis: periodic re‑evaluation of existing ES/GS data using updated gene panels, improved annotation, CNV detection, and phenotype correlation to identify previously unrecognized diagnostic variants

Recommended practiceLabs and clinicians should perform systematic reanalysis as variant evidence and phenotype knowledge evolve; documented protocols recommended

Evidence supportStudies show reanalysis increases diagnostic yield (examples: increased yield to 15.2% in an IEI cohort; literature recommends reanalysis interval of at least 18 months)

Reanalysis / Reevaluation — reinforcement definition

DefinitionReanalysis / Reevaluation: periodic reassessment of previously acquired sequencing data and variant interpretations because phenotypes and variant evidence can change over time

Operational noteLaboratories should have policies for both variant‑level and case‑level reanalysis and clinicians should provide updated phenotype/family history to support reinterpretation

Policy referenceACMG guidance supports reanalysis and recommends laboratories develop reanalysis protocols

Tiered testing — definition

DefinitionTiered testing: an approach that begins with targeted testing (single‑gene or multi‑gene panel) when appropriate, with escalation to WES/WGS if targeted testing is negative or if clinical presentation supports genome‑wide testing

When to usePreferred when a Well‑Delineated Genetic Syndrome or specific gene set is suspected to avoid unnecessary broad sequencing

GuidanceSupported by professional societies (e.g., ASHG, ACMG) emphasizing targeted testing first when clinically indicated

Well-Delineated Genetic Syndrome — updated definition present in policy

Updated definitionWell‑Delineated Genetic Syndrome: a genetic syndrome or disorder with defined clinical features for which a specific test or targeted panel is available; if suspected, single gene or targeted panel testing should be performed before WES/WGS

Testing implicationIf syndrome suspected, targeted testing is expected prior to genome‑wide methods

Policy changeDefinition clarified and added in policy revision notes

Comparator Analysis — updated definition referenced in policy

Updated definitionComparator Analysis: genetic evaluation of an individual's close relatives (e.g., trio) to aid interpretation; policy updated the definition in the revisions

Practical effectComparator analyses (concurrent or non‑concurrent) are recognized methods to improve variant interpretation and may be covered when criteria met

Policy noteComparator Analysis definition update is documented in the policy history and Definitions section

Family history information can also justify prenatal sequencing in specific scenarios (for example, a single-system fetal anomaly with a family history suggesting a genetic etiology).

Family-history documentation is recommended as standard practice when requesting WES/WGS; detailed three-generation pedigrees and a description of affected relatives assist laboratory interpretation and case-level decision-making.

Where family history suggests recessive inheritance or consanguinity, this information can meaningfully influence test selection (trio testing preference) and expected diagnostic yield.

The presence of an affected first- or second-degree relative increases the pre-test probability of a heritable condition and supports coverage when the clinical presentation criteria are otherwise met.

Providers should ensure the medical record documents the relationship and clinical features of affected relatives to justify comparator testing or family-based sequencing.

When a well-delineated genetic syndrome is suspected based on the phenotype, the policy requires targeted testing (single-gene testing or a focused multigene panel) be performed prior to WES or WGS. This tiered approach prioritizes efficient, syndrome-directed testing when a specific etiology is likely.

For prenatal WES, the policy specifies that standard cytogenetic testing (karyotype and CMA) should be performed and be nondiagnostic before prenatal WES is considered; prenatal sequencing must be ordered in consultation with or by a medical geneticist or maternal-fetal medicine specialist and use appropriate specimen types (amniotic fluid, CVS, or fetal blood/tissue).

Policy-specific eligibility details reiterate that targeted testing is preferred when a specific syndrome is suspected and that documentation of prior testing and phenotype is expected in the medical record as part of eligibility assessment.

The policy retains flexibility for clinician judgment but makes clear that genome-wide testing is intended for situations where targeted tests are unlikely to be diagnostic or when presentation is nonspecific.

The requirement to perform targeted testing first when a well-delineated syndrome is suspected is restated throughout the policy as a necessary step to ensure focused and efficient diagnostic evaluation prior to broad genome-wide testing.

This requirement applies across postnatal and prenatal contexts, with prenatal CMA/karyotype specifically noted as a prerequisite for prenatal WES except in special circumstances documented by genetics specialists.

The policy clarifies that when targeted testing is appropriate and available (i.e., a specific single-gene test or targeted panel corresponding to a well-delineated syndrome), that testing should be performed before ordering WES/WGS. This preserves targeted diagnostic efficiency and reduces unnecessary broad testing.

Providers should document why targeted testing was not chosen or was nondiagnostic when proceeding to WES/WGS.

The targeted-testing expectation is reiterated as an eligibility requirement in policy language and accompanying guidance: genome-wide tests are intended for undifferentiated or nonspecific presentations where targeted approaches are unlikely to resolve the diagnosis.

For prenatal cases, the policy requires prior nondiagnostic CMA/karyotype when prenatal WES is requested, except in exceptional situations documented by specialists.

Across policy sections, the requirement that targeted testing be performed first when a well-delineated syndrome is suspected is restated to ensure consistent application in prior-authorization and utilization-review processes.

Laboratories and ordering clinicians should document the targeted tests performed and their results when requesting WES/WGS coverage to demonstrate that the targeted-testing step was considered or attempted.

Consistent with professional guidance, the policy does not support routine prenatal WES/WGS for fetuses without anomalies. When fetal anomalies are absent and standard prenatal tests are normal, the low incremental diagnostic yield does not justify routine genome-wide sequencing.

Prenatal WES/WGS coverage is intended for cases with documented fetal structural anomalies or specific circumstances identified by genetics specialists and multidisciplinary review.

The policy repeats that prenatal cell-free fetal DNA testing for the purpose of performing WES/WGS, preimplantation genetic testing in embryos using broad sequencing, and routine outpatient rapid/ultra-rapid sequencing are not covered indications.

These exclusions reflect both current evidence limitations and appropriate clinical application boundaries for genome-wide testing technologies.

Again emphasizing exclusions: prenatal cell-free fetal DNA to drive WES/WGS, PGT in embryos using WES/WGS, and outpatient rapid/ultra-rapid WES/WGS are listed as not covered because available evidence does not support their routine clinical use.

The policy confines coverage of rapid sequencing to critically ill inpatient settings where demonstrated clinical utility exists.

coverage_definition_update

Added and clarified coverage pathways for non-concurrent Comparator Analysis and reanalysis of prior WES/WGS, including an explicit >=18-month reanalysis interval and conditions under which reanalysis and non-concurrent comparator analysis are medically necessary.

administrative

Added medical records documentation language and updated definitions (added ASD, Congenital Anomaly, Epileptic Encephalopathy, Targeted Panel, Well-Delineated Genetic Syndrome; removed NGS and VUS definitions) and updated Description of Services, Clinical Evidence, and References; archived previous version CS150NM.D.